ArriVent BioPharma, Inc. (AVBP)
AVBP moved a median of -0.54% 30 minutes after news, and -0.83% by the close. How AVBP actually reacts to news — the realized, point-in-time move the market made, measured across 158 labeled events over the last three years with zero look-ahead.
AVBP’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 42% | 150 |
| 30-min | -0.54% | 40% | 157 |
| 60-min | -0.60% | 41% | 158 |
| to close | -0.83% | 38% | 158 |
| Middle 50% of AVBP reactions | -2.08% to +1.31% |
|---|---|
| Median reaction (30-min) | -0.54% |
| Measured reactions | 158 |
Half of all ArriVent BioPharma, Inc. news events land between -2.08% and +1.31% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How AVBP reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Coverage initiations | 41 | -0.85% | 20% | -2.15% |
| Rating reiterations | 45 | -0.30% | 36% | -1.55% |
| Price-target raises | 12 | -0.60% | 42% | -1.49% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 3 further classes were observed with fewer than 10 measured events and are not published. See how AVBP ranks against every other measured name →
That’s how AVBP usually reacts — get an email when it moves on news →Email me when AVBP moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to AVBP's baseline. Nothing else.
Recent AVBP events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against ArriVent BioPharma, Inc. (AVBP) and Encourages Stockholders to Learn More About the Investigation | Press release | ACCESS Newswire | +0.21% | -0.51% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages ArriVent BioPharma, Inc. (AVBP) Investors to Inquire about Securities Investigation | Press release | ACCESS Newswire | +0.24% | +1.33% | |
| Form 8-K ArriVent BioPharma, Inc. For: Oct 12 | SEC filing · Form 8-K | SEC EDGAR | +0.12% | -1.17% | |
| ArriVent Announces First Patient Dosed with Novel Tetravalent MUC16/NaPi2b Dual Target ADC, ARR-002 | Press release | GlobeNewswire | +0.12% | -1.17% | |
| AVBP Investors with $100,000 in Losses Have Opportunity to Join ArriVent BioPharma, Inc. Fraud Investigation with SBS Law | Press release | Business Wire | -0.72% | +0.54% | |
| ArriVent Announces Program Update from the Phase 3 FURVENT Trial of Firmonertinib in First-Line EGFR Exon 20 Insertion Mutant NSCLC | Press release | GlobeNewswire | -2.87% | +25.44% | |
| Form 8-K ArriVent BioPharma, Inc. For: Oct 06 | SEC filing · Form 8-K | SEC EDGAR | -2.87% | +25.44% | |
| ArriVent BioPharma Reports Second Quarter 2026 Financial Results | Press release | GlobeNewswire | +0.03% | -2.38% | |
| Form 10-Q ArriVent BioPharma, Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.03% | -2.38% | |
| Form 8-K ArriVent BioPharma, Inc. For: Aug 11 | SEC filing · Form 8-K | SEC EDGAR | +0.03% | -2.38% | |
| Form 8-K ArriVent BioPharma, Inc. For: Jun 18 | SEC filing · Form 8-K | SEC EDGAR | +1.80% | +3.81% | |
| ArriVent BioPharma Reports First Quarter 2026 Financial Results | Press release | GlobeNewswire | -3.77% | +2.04% | |
| Form 10-Q ArriVent BioPharma, Inc. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -3.77% | +2.04% | |
| Form 8-K ArriVent BioPharma, Inc. For: May 11 | SEC filing · Form 8-K | SEC EDGAR | -3.77% | +2.04% | |
| ArriVent Announces IND Clearance for Novel Tetravalent MUC16/NaPi2b Targeting ADC ARR-002 with Initial Focus in Ovarian and Endometrial Cancers | Press release | GlobeNewswire | -1.15% | -2.50% | |
| Form ARS ArriVent BioPharma, Inc. For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | -0.80% | +0.64% | |
| Form DEF 14A ArriVent BioPharma, Inc. For: Jun 18 | SEC filing · Form DEF | SEC EDGAR | -0.80% | +0.64% | |
| Form DEFA14A ArriVent BioPharma, Inc. | SEC filing · Form DEFA14A | SEC EDGAR | -0.80% | +0.64% | |
| Aarvik Therapeutics Showcases Novel ADC Molecules Based On MUTTA™ and AQUALINK™ Platforms at AACR 2026 | Press release | Business Wire | -2.18% | -7.84% | |
| ArriVent to Present Two Preclinical Posters on the EGFR Inhibitor Firmonertinib and on the Novel dual-target MUC16/NaPi2b Tetravalent ADC ARR-002 at the 2026 AACR Annual Meeting | Press release | GlobeNewswire | -2.18% | -7.84% | |
| Form 8-K ArriVent BioPharma, Inc. For: Mar 17 | SEC filing · Form 8-K | SEC EDGAR | -2.18% | -7.84% | |
| ArriVent BioPharma Reports Full Year 2025 Financial Results | Press release | GlobeNewswire | -0.79% | -7.79% | |
| Form 10-K ArriVent BioPharma, Inc. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -0.79% | -7.79% | |
| Form 8-K ArriVent BioPharma, Inc. For: Mar 05 | SEC filing · Form 8-K | SEC EDGAR | -0.79% | -7.79% | |
| Form S-8 ArriVent BioPharma, Inc. | SEC filing · Form S-8 | SEC EDGAR | -0.79% | -7.79% | |
| EGFR-NSCLC Market to Observe Stunning Growth at a CAGR of 9.6% During the Forecast Period (2025-2034) | DelveInsight | Press release | PR Newswire | +4.04% | +1.77% | |
| $207B Market Shift: The Race for Fast Track Approval in Oncology | Press release | PR Newswire | -2.89% | -7.17% | |
| Fast-Tracking the $537B Cancer Cure: How Accelerated Approvals Reshaping Oncology in 2026 | Press release | PR Newswire | +0.31% | +4.39% | |
| ArriVent Announces First Patient Dosed in Global Pivotal Phase 3 ALPACCA Trial Evaluating Firmonertinib for First-Line Treatment of EGFR PACC Mutant Non-Small Cell Lung Cancer | Press release | GlobeNewswire | +0.97% | +1.59% | |
| Immunotherapy Breakthroughs Turn Cold GI Tumors Hot as Market Tops $443B | Press release | PR Newswire | -0.46% | +0.48% | |
| ArriVent BioPharma Reports Third Quarter 2025 Financial Results | Press release | GlobeNewswire | -0.27% | -0.38% | |
| Form 10-Q ArriVent BioPharma, Inc. For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | -0.27% | -0.38% | |
| Form 8-K ArriVent BioPharma, Inc. For: Nov 10 | SEC filing · Form 8-K | SEC EDGAR | -0.27% | -0.38% | |
| ArriVent Appoints Brent S. Rice as Chief Commercial Officer | Press release | GlobeNewswire | +0.48% | -1.99% | |
| Arrivent Presents the Final Analysis of Firmonertinib Monotherapy Data from Global Phase 1b Study in EGFR PACC Mutant Non-Small Cell Lung Cancer at the 2025 World Conference on Lung Cancer | Press release | GlobeNewswire | +0.89% | -1.98% | |
| Form 8-K ArriVent BioPharma, Inc. For: Sep 09 | SEC filing · Form 8-K | SEC EDGAR | +0.89% | -1.98% | |
| ArriVent BioPharma Reports Second Quarter 2025 Financial Results | Press release | GlobeNewswire | -2.30% | -4.61% | |
| Form 10-Q ArriVent BioPharma, Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -2.30% | -4.61% | |
| Form 8-K ArriVent BioPharma, Inc. For: Aug 11 | SEC filing · Form 8-K | SEC EDGAR | -2.30% | -4.61% | |
| ArriVent’s Topline Pivotal Phase 3 FURVENT Data for Firmonertinib in First-Line NSCLC EGFR Exon20 Insertion Mutations is Projected to be Early 2026 | Press release | GlobeNewswire | +1.13% | -2.93% | |
| Form 8-K ArriVent BioPharma, Inc. For: Jul 21 | SEC filing · Form 8-K | SEC EDGAR | +1.13% | -2.93% | |
| Form 8-K ArriVent BioPharma, Inc. For: Jul 01 | SEC filing · Form 8-K | SEC EDGAR | -3.54% | -2.03% | |
| ArriVent Announces Pricing of $75 Million Public Offering of Common Stock and Pre-Funded Warrants | Press release | GlobeNewswire | +1.47% | +3.23% | |
| ArriVent Announces Proposed $75 Million Public Offering of Common Stock and Pre-Funded Warrants | Press release | GlobeNewswire | +1.47% | +3.23% | |
| ArriVent Announces Positive Interim Firmonertinib Monotherapy Data From Global Phase 1b Study in EGFR PACC Mutant Non-Small Cell Lung Cancer and Plans to Advance into a Global Pivotal Study | Press release | GlobeNewswire | +1.01% | -7.88% | |
| Form 8-K ArriVent BioPharma, Inc. For: Jun 23 | SEC filing · Form 8-K | SEC EDGAR | +1.01% | -7.88% | |
| ArriVent Announces Investor Event on Firmonertinib Path Forward for EGFR PACC Mutant NSCLC | Press release | GlobeNewswire | +1.01% | -7.88% | |
| Form 8-K ArriVent BioPharma, Inc. For: Jun 18 | SEC filing · Form 8-K | SEC EDGAR | +1.01% | -7.88% | |
| ArriVent BioPharma Reports First Quarter 2025 Financial Results | Press release | GlobeNewswire | +4.14% | -0.79% | |
| Form 10-Q ArriVent BioPharma, Inc. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -0.67% | -4.81% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the AVBP section they belong to.
Where else AVBP is measured.
AVBP earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is ArriVent BioPharma, Inc.'s median reaction calculated?
Every labeled AVBP news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 158 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 40% of AVBP's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does AVBP's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.